September 27, 2026 · AxonCPT Team · telehealth, clinical practice, ADHD assessment

DEA Special Registration for Telemedicine, Explained

DEA special registration for telemedicine is the permanent pathway DEA proposed in January 2025 to let clinicians prescribe controlled substances by telemedicine without first seeing the patient in person. Under the proposal, prescribing Schedule II stimulants such as Adderall or Vyvanse would take a separate “Advanced” registration, a registration in each state where your patients are located, extra PDMP checks, and new recordkeeping. The rule is not final yet. DEA sent a final version to the White House Office of Management and Budget (OMB) for review in August 2026, and its text has not been published [1][4][5].

Clinician using a laptop with a stethoscope nearby, preparing telemedicine prescribing documentation Photo by National Cancer Institute on Unsplash

This explainer is for psychiatric nurse practitioners (PMHNPs) who run telehealth or small practices and prescribe ADHD medication. Psychiatrists will find most of it applies to them too. It is current as of September 27, 2026, and it is not legal advice. Confirm every point with healthcare counsel and your state board before you change anything in your practice. For the wider question of what happens when the current flexibilities end, see our guide to DEA telemedicine rules for 2027. For the clinical side of remote ADHD care, see objective ADHD testing with AxonCPT.

What is the DEA special registration for telemedicine?

The Ryan Haight Act of 2008 generally requires an in-person medical evaluation before a controlled substance can be prescribed. One of the Act’s statutory exceptions is a “special registration” for telemedicine, which Congress directed DEA to create but which was never implemented [1]. On January 17, 2025, DEA published the proposed rule Special Registrations for Telemedicine and Limited State Telemedicine Registrations (90 FR 6541, Docket No. DEA-407) to fill that gap [1].

Right now, the COVID-era flexibilities still apply, under the fourth temporary extension that runs through December 31, 2026 [2][3]. Special registration is DEA’s proposed long-term replacement. According to NASCSA and McDermott Will & Schulte, DEA sent a final rule to OMB’s Office of Information and Regulatory Affairs on August 25, 2026. Its text is not public [4][5].

What are the three proposed registration types?

The proposed rule would create three categories [1]:

Registration Who it is for Schedules covered
Telemedicine Prescribing Registration Clinicians Schedule III–V
Advanced Telemedicine Prescribing Registration Specialized clinicians Schedule II–V
Telemedicine Platform Registration Covered online telemedicine platforms Schedule II–V (dispensing through registered clinicians)

ADHD stimulants such as amphetamine salts, lisdexamfetamine, and methylphenidate are Schedule II. So for most telehealth ADHD prescribers, the Advanced registration is the one that matters.

On top of the special registration, clinicians would also need a State Telemedicine Registration for each state where they treat patients, with limited exemptions for certain federal and VA practitioners [1].

Can PMHNPs get the Advanced Telemedicine Prescribing Registration?

Under the proposal, yes, with an important condition. Eligibility was limited to psychiatrists, hospice and palliative care physicians, physicians at long-term care facilities, pediatricians, neurologists, and “mid-level practitioners and physicians from other specialties who are board certified in the treatment of psychiatric or psychological disorders,” among other listed areas [1].

The proposal treats mid-levels differently from physicians. A physician could show specialized training in several ways, such as board certification, specialized training, or the share of their practice in the specialty. “Mid-level practitioners are, however, required to be board-certified under this proposed framework” [1].

What this means for PMHNPs:

  • Many PMHNPs hold a psychiatric-mental health NP board certification. Whether the final rule accepts that certification as meeting the requirement is something to confirm once the text is published.
  • Federal eligibility does not override state law. If your state restricts APRN Schedule II prescribing, or requires collaboration or supervision to prescribe it, those limits still apply, so check your board’s current rules alongside the federal text.

What safeguards would apply to Schedule II prescriptions?

The proposed rule added two Schedule II safeguards on top of registration [1]:

  1. A same-state requirement. Under proposed 21 CFR 1306.45(b), the clinician would have to be physically located in the same state as the patient when issuing a special registration prescription for a Schedule II drug.
  2. A 50% cap. Under proposed 21 CFR 1306.45(c), special registration prescriptions for Schedule II drugs would have to make up less than 50 percent of the clinician’s total Schedule II prescriptions, telemedicine and in-person combined, in a calendar month.

DEA said it might adopt one or both of these safeguards, and it asked for comment on them [1]. For a PMHNP whose practice is entirely virtual, the 50% cap is the key question. As proposed, a telehealth-only ADHD practice could not meet it without in-person Schedule II prescribing, or without patients who fall outside special registration because they have already had an in-person evaluation. Watch closely for how the final rule handles this.

What other requirements were proposed?

  • PDMP checks. Before prescribing, the clinician would verify the patient’s identity and then check PDMPs. A nationwide PDMP check was proposed with a three-year delayed effective date. Until then, the proposal called for checking the PDMPs of the patient’s state, the clinician’s state, and any states with reciprocity agreements with those states [1].
  • Identity verification and records. The proposal included patient-verification photographic records, special registration telemedicine encounter records, and credentials-verification records, all kept at the registered location [1].
  • Prescription notations. Special registration prescriptions would carry the special registration numbers of the clinician (and the platform, where one is involved) [1].
  • Reporting. Pharmacies and registrants would report special registration prescription data [1].
  • Fees. The proposal set $888 per special registration and $50 per clinician state telemedicine registration, on a three-year cycle [1].

All of this comes from the proposed rule. The final rule can change any of it, and after more than 6,400 public comments it probably will change some of it [2][4].

Why does DEA’s proposal lean so hard on safeguards?

The proposal says so directly. In a footnote, DEA cites the June 2024 arrests of a telehealth company’s founder and clinical president over an alleged scheme to distribute Adderall online, and says the allegations “underscore DEA’s need to judiciously evaluate when a practitioner has a legitimate need for a Special Registration” [1]. That case became the Done Global prosecution, which ended in convictions in November 2025 [6]. We cover the practice lessons in Lessons From the Done Global Case for ADHD Prescribers.

The regulatory direction is clear: remote Schedule II prescribing will stay possible, but you will need to be able to show your work.

Try it with your next patient. AxonCPT gives you 2 free tests every month — no card required. Send a link, your patient finishes in ~16 minutes from home, and you get a norm-referenced report instantly. Create your free account →

How should a PMHNP prepare before the final rule?

  1. Map your patients. List everyone on a Schedule II stimulant, where each patient is located, and whether you have ever evaluated them in person. That list tells you who a same-state rule, a 50% cap, or a lapse would affect.
  2. Check your credentials. Confirm your board certification status and the DEA registrations you hold in each state where your patients are located.
  3. Budget for fees and admin time. Plan for per-registration and per-state fees in case the proposed structure survives.
  4. Make PDMP documentation routine. Record every check with the date and the states you searched.
  5. Standardize the evaluation record. Every version of the rules requires a legitimate medical purpose. A consistent, documented workup (interview, history, rating scales, collateral information, and objective measures) is the strongest evidence you can have. Our guide to ADHD documentation for stimulant prescribing walks through what to include.
  6. Watch the Federal Register. Set an alert for DEA documents on the Federal Register, and read the final rule itself rather than summaries of it.

How this looks in practice

Here is a workflow that holds up under the current flexibilities and under any likely version of special registration:

  1. Video intake. Verify the patient’s identity and location, take a history, screen for substance use and comorbid conditions, and check the PDMP. Document all of it.
  2. Rating scales and collateral information. Collect self-report and, where possible, informant ratings.
  3. An objective attention measure. With AxonCPT, you send the patient a link. They complete the test in their browser at home in about 16 minutes, with no app or login. Results are compared with age- and sex-matched norms drawn from a 20,000+ reference dataset. You can see what the report looks like before you use it with a patient.
  4. Diagnostic reasoning in the note. Explain how each data source supports, or fails to support, the diagnosis. A CPT does not diagnose ADHD on its own. It is one data point among several.
  5. Measured follow-up. Retest at dose changes and track the Q1–Q4 vigilance pattern across visits, alongside patient report and side effects.

This is the same structure described in our full guide to running a telehealth ADHD evaluation.

Frequently asked questions

Is the DEA special registration final? No. As of September 27, 2026, the final rule was under OMB review, and its text had not been published [4][5]. The current flexibilities run through December 31, 2026 [2].

Do I need a special registration for patients I have already seen in person? Once a practitioner has done an in-person medical evaluation, the Ryan Haight Act’s telemedicine restrictions no longer apply to that practitioner–patient relationship, according to DEA’s Federal Register text [2]. State law and the final rule may add their own conditions, so confirm with counsel.

Would a remote CPT count as the in-person evaluation? No. A patient-administered test is an assessment tool, not a medical evaluation, and it does not satisfy any in-person requirement. What it does is add objective, dated data to the clinical record.

How much would special registration cost? The proposed fees were $888 per special registration plus $50 per clinician state telemedicine registration [1]. The final fees may be different.

Start testing your patients with AxonCPT

Special registration will make remote Schedule II prescribing more documented, not less. PMHNPs who already run a consistent, measurable evaluation will have the least to change. AxonCPT adds a norm-referenced attention measure your patient completes from home, and the report is ready the moment they finish. Create your free AxonCPT account with 2 free tests every month and no card required, or learn more at axoncpt.com.

References

  1. Drug Enforcement Administration. Special Registrations for Telemedicine and Limited State Telemedicine Registrations (proposed rule). Federal Register, 90 FR 6541, January 17, 2025.
  2. Drug Enforcement Administration & Department of Health and Human Services. Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications. Federal Register, 90 FR 61301, December 31, 2025.
  3. Drug Enforcement Administration. DEA Extends Telemedicine Flexibilities to Ensure Continued Access to Care. Press release, December 31, 2025.
  4. National Association of State Controlled Substances Authorities. DEA Gets Closer to Finalizing Telemedicine Special Registration. September 21, 2026.
  5. McDermott Will & Schulte (via Mondaq). DEA Appears Close To Finalizing Telemedicine Special Registration. September 24, 2026.
  6. U.S. Department of Justice, Office of Public Affairs. Founder/CEO and Clinical President of Digital Health Company Convicted in $100M Adderall Distribution and Health Care Fraud Scheme. November 19, 2025.